Citing Suspected Vaccine Patent Infringement, GSK Files Lawsuit Against Pfizer
Company is seeking monetary damages from the alleged violation.
Believing the multinational company violated four patents relating to the use of Antigens in Arexvy, GSK has announced the filing of a lawsuit against Pfizer. According to the documents filed in court, Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, was created with GSK’s “claimed inventions”. With GSK seeking monetary damages such as lost profits, Pfizer has denied any infringement, planning to defend its work.
As both Arexvy and Abrysvo have already received FDA approval, doses are now available to the public for use in adults over 60. As a part of legal proceedings, GSK has requested authorities to prevent Pfizer from selling its product.
Reference: GSK Sues Pfizer for Alleged RSV Vaccine Patent Infringement. BioSpace. August 2, 2023. Accessed August 3, 2023. https://www.biospace.com/article/gsk-sues-pfizer-for-alleged-rsv-vaccine-patent-infringement/?s=89
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
